the
a
to
if
is
it
of
and
or
an
as
i
me
my
long
always
we
our
ours
you
your
yours
he
she
him
his
her
hers
its
they
them
their
what
which
who
whom
this
that
am
are
was
were
be
been
being
reit
have
has
had
do
does
did
but
at
by
with
from
here
when
where
how
low
all
any
both
each
few
more
some
such
no
nor
too
very
can
will
just
about
for
on
would
like
not
in
think
because
why
using
new
review
building
should
reasons
want
jul
now
still
first
means
us
see
look
much
net
one
really
next
use
price
go
every
way
back
going
cash
time
money
total
know
even
span"
higher
average
around
buy
used
might
take
market
good
reason
company
companies
business
make
high
email
different
pm
lower
past
right
bank
made
pay
simply
many
started
cloud
need
last
years
year
start
increase
flow
big
current
already
interest
people
prices
whether
million
based
read
sell
buying
better
things
thing
another
return
returns
probably
line
strong
previous
may
including
gilead
mg
patients
press
forty
seven
remdesivir
please
lenacapavir
events
within
receive
website
said
studies
currently
per
billion
presented
kite
two
ongoing
tax
data
call
release
version
prior
common
due
drug
financial
product
complete
least
possibility
medicines
significant
product
months
fda
prep
trial
regulatory
tax
call
severe
following
follow
areas
care
operations
currently
related
acute
second
includes
today
days
statements
study
crs
percent
quarter
available
descovy
securities
support
comared
differ
ability
yescarta
sales
analysis
healthcare
anticipated
monitor
biopharmaceutical
develops
additional
biktarvy
share
countries
associated
filgotinib
research
public
approved
authorization
actual
occured
share
illnesses
subject
form
well
factors
future
risks
headquarters
announced
reported
clinical
phase
visit
act
fact
increased
week
diluted
foster
weak
offer
access
obligation
source
adults
weeks
living
visit
act
united
resistance
cautioned
day
update
cause
median
meaning
reader
response
reform
strives
demonstrated
filed
full
treatment
information
results
safety
risk
development
potential
investigational
trials
therapy
compared
medical
adverse
t
discontinue
ended
participants
historical
discontinue
chief
also
could